Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer

Ching Yao Yang, Ming Huei Fan, Carol H. Miao, Yi Jen Liao, Ray Hwang Yuan, Chao Lien Liu

Research output: Contribution to journalArticle

Abstract

Yang et al. developed armed third-generation PD-L1-targeted ACR/CAR T cells utilizing a PD-1/PD-L1 immune checkpoint axis. Both engineered CAR T cells significantly improved tumor control and survival in models of PD-L1-expressed pancreatic cancers.

Original languageEnglish
Pages (from-to)571-585
Number of pages15
JournalMolecular Therapy - Oncolytics
Volume17
DOIs
Publication statusPublished - Jun 26 2020

Keywords

  • ACR
  • CAR
  • PD-1
  • PD-L1
  • PDAC

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer'. Together they form a unique fingerprint.

  • Cite this